Milnacipran HCl
Brand Names: Savella
Methodology & AI Transparency ⓘ
Milnacipran HCl Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Milnacipran HCl is an FDA-registered prescription serotonin and norepinephrine reuptake inhibitor (oral-route administration) manufactured/labeled by Amneal Pharmaceuticals LLC under National Drug Code 65162-091, 65162-093, supplied in 12.5 mg/1 Tablet and 50 mg/1 Tablet for physician-directed therapeutic management.
- 2 Real-world patient consensus: 92% patient "Worth It" rating across 7 anonymous logs for Milnacipran HCl (RxNorm 833141).
- 3 Typical cash cost range: Dispensing cost comparison spans $22.97 mail/discount cash up to $56.28 uninsured retail (federal NADAC $3.4260).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Milnacipran HCl include nausea (9.3%), headache (8.6%), dizziness (5.8%).
Ask our AI Specialists anything about Milnacipran HCl
Milnacipran HCl Mechanism, CYP450 Pathways & DailyMed Monograph
Milnacipran HCl is an FDA-registered prescription serotonin and norepinephrine reuptake inhibitor (oral-route administration) manufactured/labeled by Amneal Pharmaceuticals LLC under National Drug Code 65162-091, 65162-093, supplied in 12.5 mg/1 Tablet and 50 mg/1 Tablet for physician-directed therapeutic management.
Pharmacologically, Milnacipran HCl functions within the Serotonin and Norepinephrine Reuptake Inhibitor class via oral-route delivery (12.5 mg/1 Tablet and 50 mg/1 Tablet), modulating target cellular receptors or enzymatic cascades while undergoing physiological hepatorenal clearance documented under FDA NDC 65162-091, 65162-093 (manufactured/labeled by Amneal Pharmaceuticals LLC).
Systemic exposure to Milnacipran HCl reflects Estimated 77%–89% oral systemic absorption for Milnacipran HCl absorption kinetics and phase i/ii hepatic conjugation of milnacipran hcl coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 9–16 hours terminal plasma half-life for Milnacipran HCl half-life window (peak plasma concentration (tmax) reached 1–4 hours post-dose for milnacipran hcl response profile).
Dosing protocols (12.5 mg/1 Tablet or 50 mg/1 Tablet or 100 mg/1 Tablet or 25 mg/1 Tablet or 12.5mg Tablet) balance efficacy (92.00% patient satisfaction across 7 logs) against nausea (9.3% of reports), headache (8.6% of reports), dizziness (5.8% of reports), with strict avoidance in known hypersensitivity to milnacipran hcl or structurally related serotonin and norepinephrine reuptake inhibitor compounds; concomitant contra-labeled cyp/transporter therapies during active milnacipran hcl administration.
Avoid overlapping serotonin and norepinephrine reuptake inhibitor prescriptions alongside Milnacipran HCl to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Milnacipran HCl dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Milnacipran HCl or structurally related serotonin and norepinephrine reuptake inhibitor compounds
- Concomitant contra-labeled CYP/transporter therapies during active Milnacipran HCl administration
Logged Side-Effect Incidence (7 Reports)
Milnacipran HCl Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Milnacipran HCl)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Safety and real-world benefits of Levomilnacipran Extended Release in children Conclusions: The high placebo response in this study prevented the detection of an effect of levomilnacipran in children and adolescents. Journal of child and adolescent psychopharmacology • 2024-06-15 • Phase III Randomized Trial | N = 134 | 88/100 | PMID 38700708 ↗ |
| Can This Approach Help? Inside the Latest Research on III. Detecting Treatment Effects in Clinical Trials With Different Indices of PERSPECTIVE: Alternative summary measures of pain intensity derived from EMA may broaden the scope of outcomes useful in pain clinical trials. The journal of pain • 2021-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33172597 ↗ |
Milnacipran HCl Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.4260/unit (~$102.78/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $22.97 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $56.28 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 7 Anonymous DotMD Community Micro-Logs | $26.42 / mo | View logs ↓ |
Milnacipran HCl Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Milnacipran HCl RxNorm Concept ID | 833141 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.4260 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $56.28 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $22.97 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 92.00% Worth It (7 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Milnacipran HCl Patient Community, Cohort Filters & Dosage Logs
Deterministic Milnacipran HCl reference combining NIH RxNorm (833141), Medicaid NADAC ($3.4260/unit), and anonymous cohort outcomes (92% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Milnacipran HCl community threads and patient logs by age, biological sex, dosage, and treatment duration.